By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Juno Therapeutics 

307 Westlake Avenue North
Suite 300
Seattle  Washington    U.S.A.
Phone: 206-582-1600 Fax: n/a


Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. Our goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.


August 5, 2013


Founders: : Hans Bishop, Richard Klausner, and Robert Nelsen

CEO and Co-founder: Hans Bishop


Please click here for job opportunities.


Please click here for clinical trial information.


Key Statistics

Ownership: Private

Web Site: Juno
Employees: n/a
Symbol: JUNO


Company News
A Look at Whether Juno (JUNO) Can Recover After Losing More Than Half Its Value in 2016 1/16/2017 6:03:42 AM
Juno (JUNO)’ And Celgene (CELG)’s Investigational Drug JCAR017 Granted Breakthrough Therapy Designation From FDA And Priority Medicines Eligibility From EMAFor Relapsed/Refractory Diffuse Large B-Cell Lymphoma 12/20/2016 12:13:45 PM
Juno (JUNO) Defeats Kite Pharma (KITE)’s Challenge To CAR T-Cell Patent 12/19/2016 9:28:48 AM
Juno (JUNO) Highlights Progress With Best-in-Class Strategy In B-Cell Malignancies At American Society of Hematology 12/7/2016 11:56:00 AM
Juno (JUNO) Presents Data From TRANSCEND Study Showing 60% Complete Response In Patients With Relapsed Or Refractory Aggressive CD19+ Non-Hodgkin Lymphoma 12/6/2016 10:45:17 AM
Juno (JUNO) Lymphoma Drug Impresses in Early Stage Study, But Fear of Cerebral Edema Looms 12/5/2016 11:09:52 AM
Juno (JUNO) Shows Off Positive Early Data in Leukemia Patients 12/5/2016 6:14:17 AM
As Rival Juno (JUNO) Falters, Kite Pharma (KITE) Touts New CAR-T Data and Maps Out BLA Submission Plans 12/5/2016 5:32:45 AM
Latest Deaths in Juno (JUNO) Trial Puts Unwanted Limelight on the FDA 11/28/2016 5:58:07 AM
Juno (JUNO) Halts CAR-T Trial for Second Time Following Additional Patient Deaths 11/23/2016 6:21:00 AM